HSC Exam Practice

Sample response. Agricultural: Bt cotton expresses a Bacillus thuringiensis Cry-toxin gene, providing pest resistance and increasing lint yield. Medical: recombinant human insulin is produced inside engineered E. coli (or yeast) host cells for diabetes treatment, replacing pig/cow-pancreas insulin. Industrial: engineered Trichoderma reesei produces cellulase enzymes used to break down plant cellulose in second-generation biofuel production. Accept also Golden Rice, recombinant hepatitis B vaccine, recombinant chymosin for cheese, etc.

Marking notes. 1 mark per correctly named benefit paired with a real example in the correct domain. A correct example placed in the wrong domain scores 0 for that entry.

Sample response. The human insulin gene is isolated and inserted into a bacterial plasmid using restriction enzymes and DNA ligase, producing a recombinant plasmid. The plasmid is transformed into a host cell such as E. coli (or, in modern industry, yeast). The host cell transcribes and translates the inserted gene, producing functional human insulin protein. Engineered host cells are grown in large fermenters, after which insulin is extracted and purified for medical use. The result is structurally identical human insulin produced at consistent scale.

Marking notes. 1 mark for naming the recombinant DNA step (insulin gene inserted into plasmid / vector). 1 mark for naming the host cell and its role as a controlled biological producer (E. coli / yeast expresses the gene). 1 mark for linking the system to the medical benefit (consistent, scalable supply of human insulin replacing animal-sourced insulin).

Sample response. An agricultural application uses genetic technologies to influence crop or livestock performance and management — for example, Roundup Ready soybean engineered for herbicide tolerance to support weed control on-farm. An industrial application uses biological systems or products in manufacturing or processing — for example, recombinant chymosin produced in engineered Aspergillus niger for cheese manufacture, replacing calf rennet.

Marking notes. 1 mark for correctly distinguishing agricultural (on-farm crop/livestock performance) from industrial (manufacturing / processing using biological systems). 1 mark for a correct named example of each. Both required for full marks.

Sample response. The statement is too weak because it fails to specify the domain, the comparison and the affected party — three things every HSC evaluation must name. It also reduces all benefits to "productivity", which ignores the medical benefit (production of useful proteins such as insulin) and the industrial benefit (large-scale biological manufacturing using enzymes such as cellulase). Finally, it ignores the biodiversity trade-off in agriculture: higher productivity from a narrow range of genotypes can reduce on-farm genetic diversity and resilience to new pests or environmental stress.

Marking notes. 1 mark for identifying that "beneficial" must be named for a domain / comparison / affected party (Card 1). 1 mark for identifying that productivity alone misses the medical and/or industrial benefit types. 1 mark for identifying the biodiversity trade-off as the specifically agricultural counterweight (Card 5).

Sample response (a). Bt cotton outperforms conventional cotton on two clear agricultural metrics: lint yield is approximately 27% higher (index 127 vs 100), and insecticide sprays per season fall by approximately 74% (index 26 vs 100). Net farm income is also 38% higher (138 vs 100), reflecting the combined yield gain and input saving.

Sample response (b). The cotton plant has been engineered to carry a Cry-toxin gene from Bacillus thuringiensis. The plant's cells transcribe and translate this gene, producing the Cry protein in plant tissue. When bollworm caterpillars feed on the cotton, the protein binds to receptors in their gut, disrupting it and killing them. Because the plant produces its own insecticide internally, less external spraying is needed, reducing crop damage and the cost of inputs while raising yield.

Sample response (c). Bt cotton is grown as a near-uniform crop expressing the same Cry-toxin. Continuous, large-scale exposure to one toxin selects strongly for rare bollworm individuals carrying resistance alleles, and their descendants come to dominate the pest population over years. This narrows pest biodiversity in a way that erodes the original benefit — exactly the lesson's warning about reliance on a narrow range of dominant genotypes. Refuge planting (some non-Bt cotton alongside Bt cotton) is used to preserve diversity and slow resistance.

Marking notes. Part (a) — 1 mark for identifying yield increase with figure; 1 mark for identifying insecticide reduction with figure. Part (b) — 1 mark for identifying Cry-toxin gene from B. thuringiensis inserted into cotton; 1 mark for explaining mechanism (toxin produced in plant tissue, kills bollworm on ingestion). Part (c) — 1 mark for identifying selection of resistant bollworms / narrowing of pest biodiversity; 1 mark for linking this to long-term loss of the benefit and the need for refuge / mixed-genotype strategies. Award 6 max.

Sample response. Genetic technologies provide benefits in all three application domains, but the kind of benefit, the relevant comparison, and the trade-offs differ. In agriculture, Bt cotton has raised lint yield by roughly 27% and cut insecticide sprays by roughly 74% in pooled trials, while Golden Rice illustrates nutritional modification by producing β-carotene (a vitamin A precursor) in the endosperm for populations with chronic vitamin A deficiency. In medicine, recombinant human insulin produced inside engineered Escherichia coli and yeast host cells now supplies essentially the entire global insulin market, replacing animal-pancreas insulin and giving consistent, sterile, structurally human protein for diabetes treatment; recombinant hepatitis B vaccine antigen, also produced in yeast, supports global childhood immunisation. In industry, engineered Trichoderma reesei produces cellulase enzymes at roughly 20× the wild-type titre, dropping enzyme cost per litre of second-generation bioethanol by an order of magnitude, while engineered Aspergillus niger produces recombinant chymosin for cheese manufacture. These are real, distinct benefits — productivity and resistance traits in agriculture, controlled biological production of useful proteins in medicine, and large-scale enzyme manufacture in industry — and they cannot be reduced to one general "efficiency" claim.

The strongest agricultural benefits are tied to a real trade-off. Reliance on a narrow range of high-performing genotypes — Bt cotton, Roundup Ready soybean, Cavendish bananas — concentrates production on a small genetic base, narrowing biodiversity and reducing resilience. Bollworm resistance to Cry-toxins is now rising in Bt-cotton regions; Cavendish bananas are globally vulnerable to Fusarium TR4. This trade-off operates because the system has been optimised toward a single dominant genotype, exactly the warning in Card 5. Medical and industrial domains share some access-and-cost trade-offs (e.g. recombinant insulin's affordability in low-income countries) but generally not this kind of ecological trade-off, because production happens inside contained fermenters rather than across landscapes.

Therefore genetic technologies can be highly beneficial, but the type and extent of benefit depend on the application. The strongest HSC judgement names the domain, names a specific real example, names the comparator, and weighs the benefit against domain-specific trade-offs — particularly the biodiversity trade-off in agriculture — rather than asserting the technology is beneficial in general.

Marking notes. 1 mark — agricultural benefit named with a real example (Bt cotton, Golden Rice, Roundup Ready, AquAdvantage salmon, etc.). 1 mark — medical benefit named with a real example (recombinant insulin, hepatitis B vaccine, Factor VIII, etc.) and link to controlled biological production. 1 mark — industrial benefit named with a real example (cellulase, chymosin, subtilisin, etc.) and link to large-scale biological manufacturing. 1 mark — defines what counts as a "benefit" (domain, comparison, affected party) rather than treating "beneficial" as self-evident. 1 mark — explicit biodiversity trade-off in agriculture, with mechanism (narrow range of genotypes → reduced resilience, e.g. rising Cry-resistance / Cavendish vulnerability). 1 mark — contrasts the agricultural trade-off with the medical / industrial domains (contained systems, mostly access/cost trade-offs). 1 mark — conditional, balanced concluding judgement using lesson terminology ("can be highly beneficial", "depends on the application", "must be weighed against"). 1 mark — sustained HSC register: precise terminology, coherent paragraphing, no slogans.